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Sllnllnary 
High-grade malignant nonHodgkin's lymphomas-five lymphoblastic, three pleomorphic, and 
two immunoblastic-developed in 10/25 cynomolgus monkeys (Macacafascicularis)  followed for 
up to 746 d after infection with simian immunodeficiency  virus, strain SIVsm. These lymphomas 
were shown to be associated with an Epstein-Barr (EB)-like cynomolgus  B-lymphotropic herpesvirus 
(CBLV) by electron microscopy, by Southern blot hybridization with probes against human EBV, 
and by the expression of antigens corresponding to EBV-associated nuclear antigens (EBNAs) 
involved in human B cell transformation. Southern blot demonstration ofimmunoglobulin gene 
rearrangements and homogeneous EBV episomes indicated that all the lymphomas were CBLV- 
associated monoclonal B cell proliferations.  Our findings suggest that these tumors correspond 
to the EBV-associated  malignant lymphomas in acquired immunodeficiency  syndrome with respect 
to clinical, morphological, phenotypic, and genotypic characteristics. The particular susceptibility 
of SIVsm immunodeficient cynomolgus monkeys for CBLV-associated lymphomagenesis appears 
therefore a useful model for EBV-associated lymphomas in humans. 
p atients with AIDS are at high risk to develop malignant 
lymphoma (1). The majority of these AIDS-related lym- 
phomas (ARL) are high-grade malignant, B ceU-derived,  with 
extranodal growth at uncommon anatomical sites, and with 
a restricted range of morphologies (2--4). Molecular charac- 
terization has revealed subtypes with respect to clonality, as- 
sociation of EBV, and involvement of the c-myc oncogene 
(2-6). In those ARL associated with EBV, the virus is sug- 
gested to play an important pathogenic role (7,  8). 
Infection of macaques with SIV has recently been estab- 
lished as a primate model for human AIDS (9).  In these 
monkeys infected with various strains of SIV, development 
of lymphoproliferations or lymphomas associated with im- 
munodeficiency have been reported in some animals (10). 
When examined, these lymphomas were orb cell origin, and 
association with an EB-like virus was occasionally inferred 
(10, 11). Recently, we reported a high incidence of malig- 
nant B cell lymphomas in a cohort of cynomolgus monkeys 
experimentally infected with SIVsm (12). Here we demon- 
strate that all these lymphomas are monoclonal by Ig gene 
rearrangement, and are associated with an EBV-like cyno- 
molgus B lymphotropic herpesvirus (CBLV). We provide evi- 
dence for the expression in the tumor cells of a nuclear mole- 
cule similar to the EBV-associated nuclear antigen type 2 
(EBNA-2),  suggesting an important role of the CBLV in the 
pathogenesis of the malignant lymphomas. The high inci- 
dence of CBLV-associated B cell malignancies in cynomolgus 
monkeys infected with SIVsm, and their close resemblance 
to EBV-associated lymphomas in HIV patients provides a 
model for studies on the relative importance of immunosup- 
pressive and oncogenic factors in AIDS lymphomagenesis. 
Materials and Methods 
SIV Inoculation and Serology.  25  wild  caught  cynomolgus 
monkeys (Macaca  fascicularis) were inoculated with SIVsm (strain 
SMM-3) as previously  described  (13). Screening  of monkey sera for 
IgG antibodies to viral capsid antigen (VCA) of human EBV was 
performed according to previously published methods (14). All 
animals used in this study were maintained and handled according 
to the Guidelines  of the Swedish  Ethics Committee of Animal Pro- 
tection. Animals with tumors were killed within one week after 
tumor presentation. 
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copy.  Tissue  and  tumor  biopsies  were  partly  frozen  in  liquid 
nitrogen  for DNA extraction  and immunohistochemistry,  partly 
fixed in 10% buffered formalin or Carnoy's fixative, and processed 
for conventional histopathology. 
Nuclear antigens (EBNAs) were studied by an anticomplement 
immunofluorescence assay (ACIF) on frozen sections and cytospins 
of cultured tumor cells fixed with methanol/acetone  (1:1; -20~ 
5 min) using six positive (HK, FF, LH, SP, IA, 107) and five nega- 
tive (IE, GD, PB, ER, SN) human  reference sera, as well as sera 
from tumor-bearing  animals before and after SIV infection (15). 
Reactivity  of lymphoma  cells was evaluated by fluorescence mi- 
croscopy (Zeiss, Obercochen,  Germany), and compared with that 
of the EBNA-positive RAJI clone NC37. 
Immunostaining  for  an  EBNA-2-1ike molecule  (mAb PE-2) 
(16) was performed  on acetone-fixed frozen lymphoma  sections 
with a double indirect immunoperoxidase  method as previously 
described (12). 
For electron microscopy (EM), cultured cells (see below) from 
tumor nos. 6 and 9 were spun down, and the pellets fixed in 2% 
glutaraldehyde/2%  paraformaldehyde,  and  in  OsO4,  and  em- 
bedded in Spurt resin (Polysciences  Inc., Warrington,  PA). Ultra- 
thin sections were stained with uranylacetate and lead and exam- 
ined in a JEOL 100 TEM. 
Cell Cultures.  Lymphoma cell cultures were established from 
minced tumor tissues and single cell suspensions were grown in 
RPMI, supplemented with 15% FCS, penicillin, and streptomycin. 
DNA Isolation and Southern Blotting.  DNA was isolated from 
lymphoma  and nonlymphomatous  tissue of the same animal, as 
well as from cultured  cells of one of the tumors (no. 9; A4-27) 
according to standard procedures (17), electrophoresed on 0.6% 
agarose gels, and transferred  to nylon  membranes  (17). Human 
placental DNA was included as a control. 
Hybridization for Ig gene rearrangement was done with a probe 
specific for human JR (2.5 kb) (18). Presence of DNA hybridizing 
with sequences of EBV was probed by hybridization with a cloned 
3.1-kb BamHI W  fragment directed against the long internal re- 
peat sequence of human EBV (19) on BamHI-digested  DNA. In 
addition,  eight  tumors and one cell line were tested on BamHI- 
digested  DNA by hybridization  with  a  1.9-kb XhoI  fragment 
against a sequence right to the terminal repeats of EBV, which are 
intracellularly joined to form closed episomal viral DNA and are 
useful for determination of clonality (20). DNA isolated from B95-8 
and RAJI cells was included as a positive control in all EBV hybridi- 
zations, c-myc  was detected with a 1.8-kb probe against the 3rd 
exon (21) (Oncor Inc., Gaithersburg, MD) on EcoRI and HindlII- 
digested tumor and nontumor DNA. All DNA probes were la- 
beled  with  p32  (17) (random  primed  labeling  kit;  Boehringer 
Mannheim,  Mannheim,  Germany). 
Results and Discussion 
The  previously described morphology  and B cell origin 
of the examined monkey lymphomas suggested similarities 
with the EBV-associated subtype of AIDS-related lymphomas 
in  humans  (12).  Sera  from  the  tumor-bearing  and  other 
monkeys were therefore screened for EBV-spedfic antibodies. 
IgG  antibodies  reactive with  VCA in  titers  ranging  from 
1/40-1/320 were detected in multiple serum samples taken 
before, and at various stages after SIV infection from 13/25 
monkeys tested,  including eight with lymphomas.  No sig- 
nificant difference was observed in antibody titers of tumor- 
bearing  and other SIV-infected monkeys.  Also,  eight  HIV- 
2-infected animals  without  any sign of immunodeficiency, 
as well as one uninfected animal,  had anti-VCA titers up to 
1/640 in  three serum  samples from  each animal.  As these 
serological findings strongly suggested that the cynomolgus 
monkeys were infected with an EB-like virus before SIV in- 
fection, we looked for the presence of such a virus in lym- 
phoma  cells by EM,  DNA  and  antigen  analyses. 
Characteristic  EBV-like particles  (22) were found ultrastruc- 
turally in a small number of cells in two cell lines established 
from different lymphoma biopsies (Fig.  1). Furthermore,  a 
nuclear antigen reactivity could be demonstrated in most cells 
of these two cell lines,  and in frozen sections of 8/10 tumor 
biopsies by ACIF with four reference EBNA-positive human 
sera (Table 1) (Fig.  2 a). Five EBNA-negative human sera did 
not show any reactivity with the same lymphoma sections 
and cultured cells. Serum samples of tumor-bearing animals 
taken before or in early and late stages during SIV infection 
showed a typical EBNAolike reactivity with cells of autolo- 
gous lymphomas (Fig.  2 b), as well as in NC37 (Raji) cells 
(not shown). This reactivity was usually seen in most of the 
lymphoma cells, strongly suggesting the expression of EBNA- 
like antigens  in  these lymphomas. 
Similarly, immunostaining with the EBNA-2-specific mAb 
PE-2 also  showed a nuclear reactivity in a variable number 
of the cells of all tumors (Fig. 2 c and Table 1) and of cytospins 
from  the  cultured  lymphoma  cells.  Taken  together,  8/10 
tumors showed an EBNA-like reactivity with the polyvalent 
human sera in the ACIF assay, and all including the two ACIF- 
negative cases reacted with the anti-EBNA-2 mAb PE-2 (Table 
1). The reactivity of all tumors with the anti-EBNA-2 mAb, 
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and Cultured L ymphoma Cells 
Southern blot  analysis 
CBLVS 
Immunostaining 
ACIF  ~  EBNA-2** 
Tumor  Histology  G-R*  c-mycI  BamHI W  XhoI II  (human sera)  (mAb PE-2) 
1  Lymphoblastic  1, 2  G  Positive  13; 6  + +/+ + +  + + 
2  Immunoblastic/  1  G  Positive  13; 6  +/+ + +  + + + 
plasmacytic 
3  Lymphoblastic  1  G  Positive  13; 9  +/+ + +  + + + 
4  Lymphoblastic  1, 2  G  Positive  13; 6  +/+ + +  + + + 
5  Pleomorphic  ND  ND  ND  ND  +/+ + +  + + + 
6  Lymphoblastic  1,  2  G  Positive  13; 9  + +/+ + +  + + 
7  Lymphoblastic  1, 2  G  Positive  13; 6  +/+ +  + + 
8  Pleomorphic  1  G  Positive  13; 9  n.n.  + + 
9  Immunoblastic  1, 2  G  Positive  13; 6  +/+ + +  + + + 
10  Pleomorphic  1, 2  G  Positive  13; 9  n.n  + + + 
Cell line 
Al(no. 6)  Lymphoblastic  ND  ND  ND  ND  + / + +  ND 
A4(no.  9)  Immunoblastic  1, 2  G  Positive  13  + / + +  + + 
*  G-R, Ig gene rearrangement numbers specify  clonal bands. 
* G, germine configuration. 
S  Cynomolgus  B lymphotrophic  virus. 
II Numbers specify  molecular weight of observed bands. 
Range of minimum  and maximum  positivity  with five  different  EBNA-positive  human  reference  sera, all diluted 1:10, when compared with their 
reactivity with NC37 control cells, n.n., non nuclear staining. 
** Positivity score: +, 0-10%;  + +, 10-30%;  + + +, >30% positively  stained cells. 
but not with two EBNA-l-specific human sera (JA, 107) (23) 
indicates that the demonstrated crossreacting human antibodies 
are predominantly directed against a cyno-EBNA-2-1ike an- 
tigen. This is in accordance with observations made by DiUner 
et al.  (24) in a comparison of human and simian EBNAs. 
Considering the important role  of EBNA-2  in  the EBV- 
induced growth transformation of human B cells (16), our 
findings suggest a similar role for the CBLV in the lymphoma- 
genic  process  in  the  SIV-immunosuppressed  cynomolgus 
monkeys. 
In Southern blot studies of nine tumors and one cultured 
cell line (A4;  no.  9),  all were shown to contain DNA se- 
quences  crosshybridizing with a 3.1-kb  BamHI W  probe 
against the long internal repeat of EBV, indicating the pres- 
ence of EBV-like DNA sequences  (Fig.  3 a) (Table 1).  Hy- 
bridization of the same tumors with a 1.9-kb  XhoI probe 
covering the exons coding for the latent membrane protein 
(LMP) in human EBV gave no signal at the same hybridiza- 
tion conditions, but a weak signal at lower stringency (Fig. 
3 b) (Table 1). This may indicate that the CBLV has a rela- 
tively low homology to the human EBV  sequence  in this 
region, and/or that this sequence  is in a different context, 
since the B-95-8  control cells give smaller fragments (Fig. 
3 b). As the XhoI fragment in human EBV is localized close 
to the terminal repeats generating covalently closed episomal 
DNA in all virus-carrying cells, the observed single band (13 
kb) (Fig. 3 b) could represent a donal episomal form of the 
CBLV (20),  while the appearance  of a second band (,o6 or 
9 kb, respectively) can be due to integration or a more com- 
plex arrangement. Crosshybridization to cellular monkey se- 
quences  is excluded by the negative findings in the control 
tissues  (Fig.  3  b). 
Clonality of the lymphoma cell populations was evident 
from Southern blots showing clonal Ig gene rearrangements 
of the H chain locus with a human J,-specific probe in nine 
lymphomas tested (Fig.  3 c and Table 1). The cultured cell 
line (A4; no. 9) had an identical Ig gene rearrangement pat- 
tern to that seen in the primary lymphoma biopsy, besides 
a loss of the germline fragment (3 kb) (Fig. 3 c), indicating 
that the in vitro growing cells indeed were derived from the 
primary tumor done. Southern blotting with a probe specific 
for the 3rd exon of the m  F  oncogene after EcoRI and HindlII 
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By ACIF staining in tumor cell nuclei with a human EBNA-positive  ref- 
erence  serum; (b) With autologous monkey serum on a lymphoma biopsy 
(no. 9;  x400);  (c) Immunohistochemical staining for EBNA-2 in the 
majority of tumor cell nuclei of a lymphoma biopsy (no. 9; mAb PE-2; 
double indirect peroxidase method,  x600). 
(data not shown) digestion of DNA from nine tumors and 
the A4-cdls revealed a germline configuration (Fig. 3 d and 
Table  1). 
The studied malignant  lymphomas in the present  series 
of SIVsm-immunosuppressed monkeys seem to be homoge- 
neous with respect to clonality, the presence of an EBV-like 
B lymphotropic cynomolgus herpesvirus  (CBLV), and lack 
of detectable myc rearrangement. The expression by the lym- 
phoma ceils of an EBNA-2-1ike  protein in  the lymphoma 
cells indeed suggests that this CBLV may have an important 
role in  the  pathogenesis  of the  examined  malignant  lym- 
phomas.  The apparent clonal episomal virus expression and 
the demonstration of EBNA-Iike viral antigens in most tumor 
cells indicates that the viral infection preceded the clonal B 
cell proliferation (8, 20).  In vitro studies are needed to fur- 
ther elucidate the functional characteristics of the CBLV with 
regard to polyclonal B  cell activation,  transformation,  and 
other pathogenic mechanisms of importance for the outgrowth 
of malignant B cell clones. Furthermore, the high frequency 
of CBLV-associated lymphomas observed in our monkeys may 
relate to an indirect transforming effect of SIV by CBLV up- 
regulation and c-myc activation, as recently suggested for HIV 
and EBV (25). The monkey model described may therefore 
become an important tool for studies of the interactions be- 
tween EBV and immunodeficiency viruses in the pathogen- 
esis of malignant  lymphomas  in  AIDS. 
Figure 3.  Southern blot results from two (nos. 8 and 9) lymphomas showing: (a) DNA sequences  of tumor no. 9 and corresponding cultured cells 
(/14) crosshybridizing  with a 3.1 kb BamHI W probe against the long internal repeat of the EBV. Raji ceils and the B95-8 lymphoblastoid cell line 
are included as positive controls (BamHl digest). (7") Tumor CNA.  (C) Nonlymphomatous tissue from the same animal. (b) Hybridization with a 
1.9-kb XhoI probe to the right terminal repeats of EBV. One band in the lymphoma DNA is seen at ',~13 kb, strongly suggesting the presence of 
a donal episomal population of the EBV-like  virus. A second signal is of variable molecular mass (6 and 9 kb, respectively).  The signals in the tumor 
DNA were detected under low stringency (filters  were washed twice with 3x SSC for 20 min, and once with lx SSC for 10 min). The cells cultured 
from tumor no. 9 (A4) exhibit a single signal at 13 kb, RAJI cells show a single band at 21 kb, and multiple bands are seen in the lymphoblastoid 
cell line B95-8 under high stringency conditions (BamHI digest). (c) Rearrangement of Ig H chain genes with a human J,-specific probe. Cultured 
cells from one tumor (A4; no. 9) show a rearrangement pattern identical to that seen in the primary lymphoma biopsy, accompanied  by a loss of 
the germline (at "~3 kb). Human placenta was included as a control (BglII digest). (d) Hybridization for c-myc  with a 1.8-kb probe covering the 3rd 
exon showing  a germline  band at 13 kb without any evidence  of  rearrangements  of  the c-m?c  gene. Human placenta  was included  as a control (EcoRI digest). 
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